We have a diversified and balanced clinical development pipeline, covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

The company also has a vaccine platform discovering and developing glycoconjugate vaccines containing synthetic antigenic glycan molecules with and without a carrier protein to prevent infection.

The pipeline comprises more than 10 compounds, with half in late-stage development. The development of an innovative compound into a future therapy is a complex undertaking, which inevitably involves an element of risk. With our scientific, data-driven approach helping to mitigate risk at each step, we have already brought two products to the market, QUVIVIQ^™ in the US and Europe, and PIVLAZ^® in Japan (license rights later assigned to Nxera Pharma (previously known as Sosei Heptares) for Japan, South Korea and APAC (excluding China)), with aprocitentan currently approved in the US under the tradename TRYVIO™  and undergoing regulatory assessment in the EU.

We now aim to broaden the availability of our products by launching QUVIVIQ in additional markets and bring additional products from our late-stage development pipeline, such as lucerastat, selatogrel, and cenerimod, to the market in the near term.

We have taken a simple, efficient approach to our first product launches, utilizing shared, best in class platforms and ways of working that enable fast decision-making and cost effective growth. We will continue to focus on transforming treatment in underserved markets, such as insomnia, using scientific and medical evidence to engage effectively with experts in the field and with payors. We plan to remain flexible and nimble in the way we commercialize our portfolio. We have built the core capabilities required to successfully launch our products, while also entering into partnerships where we need support to reach a primary care market.

We have established commercial operations in the US and the major European markets, with experienced leadership teams and strategic locations. We have also established a robust and lean global supply chain function to ensure consistent supplies of our innovative medicines to patients.

— Jean-Paul Clozel, CEO

We believe that we have the potential to generate significant revenues from our innovative portfolio, which now includes a product on the market in the US and several European countries, and another product under review by US and EU health authorities.

To maximize the medical value of our discoveries and to provide a source of liquidity in the short to medium term, we have entered into several collaborative partnerships with pharmaceutical companies. These include development, commercialization, and revenuesharing agreements, under which we are eligible to receive milestone payments based on the progress of the development compound in question.

Furthermore, with several unencumbered assets in clinical development, additional contract revenue from partnerships and/or out-licensing remains an option for us.

— André C. Muller, CFO

In addition to several drug candidates in the early stages of clinical and preclinical development, we must continue with our discovery efforts, to maintain a steady supply of innovative compounds to our pipeline. We aim to create a pipeline with a sales potential of at least CHF 5 billion.

— Martine Clozel, CSO

We integrate computational tools and digital technologies at various stages of the drug discovery, development, and commercialization process, so as to maximize our potential and bring breakthrough medicines to patients.

We look for creative ways to harness advances in technology to focus on novel targets and use new drug development methods. All functions involved in drug discovery and in clinical and pharmaceutical development are streamlined to assist in the delivery of tailored, high-quality medicines.

— Jean-Paul Clozel, CEO